Clinical Trial Update: Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing a Phase 1/2 study evaluating the safety and efficacy of TNX-650 for refractory Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• TNX-650

Snippet

Sponsor: Tanox | Conditions: Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN